医学
无线电技术
磁共振成像
导管癌
免疫组织化学
回顾性队列研究
放射科
微钙化
危险分层
病理
孕酮受体
肿瘤科
癌
雌激素受体
乳腺摄影术
多元分析
组织病理学
特征(语言学)
乳房磁振造影
内科学
分割
乳腺癌
乳房成像
解剖病理学
试验预测值
作者
A. Tan,Amir Bakhshandehpour,Ümran Esen,Jale Karakaya,Gamze Durhan
标识
DOI:10.1177/02841851261472084
摘要
Background Differentiating the immunohistochemical and histopathological features of ductal carcinoma in situ (DCIS) lesions is critical to potentially enable future tailored treatment options and de-escalation strategies. Purpose To investigate the potential of magnetic resonance imaging (MRI) radiomics for the non-invasive prediction of estrogen receptor (ER), progesterone receptor (PR), grade, microcalcification, and comedonecrosis in DCIS lesions, which may provide implications for risk stratification. Material and Methods This single-center retrospective study included 75 DCIS patients who had undergone pre-treatment MRI and were diagnosed through surgical pathology at our hospital between January 2010 and December 2023. The 75 segmented lesions were categorized into subgroups based on ER, PR, comedonecrosis, microcalcification status, and grade. Model performance was then assessed. Manual segmentation was performed on the second phase of dynamic contrast-enhanced T1 MRI. The BORUTA method was employed for feature selection. Using the selected features, the classification performance of various models was examined to determine if DCIS could be differentiated across the five subgroups. Results In total, 75 patients with DCIS (74 women; mean age=49.36±11.28 years) were evaluated. Effective discrimination in subgroups was as follows: comedonecrosis, n =5; grade, n =1; ER, n =3; and PR, n =5. Radiomic model performance varied across subgroups, with F1 scores observed in the subgroups: ER, 0.8293–0.9091; PR, 0.7796–1; grade, 0.9051–0.9538; microcalcification, 0.9126–0.9895; and comedonecrosis, 0.8247–1. Conclusion MRI radiomics demonstrates significant potential in non-invasively differentiating key immunohistochemical and histopathological features of DCIS. This approach may provide complementary information for DCIS characterization and risk stratification, although further validation is required before clinical implementation.
科研通智能强力驱动
Strongly Powered by AbleSci AI